COMMUNIQUÉS West-GlobeNewswire

Relation Announces Expanded Collaboration with GSK
30/07/2026
Up to $110 million upfront and success-based milestones collaboration will generate large-scale human cellular perturbation datasets to advance understanding of disease biology LONDON, July 30, 2026 (GLOBE NEWSWIRE) -- [...]
Actimed Therapeutics Strengthens Board with Appointment of Dr. Anders Ullman
30/07/2026
London, UK – 30 July 2026. Actimed Therapeutics Ltd (“Actimed”), a UK based clinical stage specialty pharmaceutical company focused on bringing innovation to the treatment of cancer cachexia and other muscle wasting [...]
Relation unveils MORGAN, the next-generation model of cellular biology
30/07/2026
LONDON, July 30, 2026 (GLOBE NEWSWIRE) -- Relation today announced MORGAN (Multi-Omic Regulatory Genomics using Artificial Neural Networks), our flagship cellular foundation model designed to transform how new biology [...]
Ipsen delivers excellent H1 2026 results and upgrades its full-year guidance
30/07/2026
H1 2026 results with sales growth of 23.5% at CER 1 , or 20.4% as reported, with the portfolio beyond Somatuline ® achieving sales growth of 24.8% 1 and core operating income of €845m, growing by 28.8% as reported, with [...]
Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded
30/07/2026
Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded July 30, 2026 Q2 sales growth of 17.8% at CER 1 and business earnings per share (EPS) 2 of €2.09 Pharma launches sales increased [...]
Curium advances plans for second investment in Romania to expand access to advanced nuclear medicine
30/07/2026
Proposed expansion in the Cluj-Napoca region intended to strengthen PET imaging supply and support continued development of regional nuclear medicine services BOSTON, July 30, 2026 (GLOBE NEWSWIRE) -- Curium™ announced [...]
Communiqué de presse : T2 2026 : croissance à deux chiffres du chiffre d’affaires et forte progression du BNPA ; révision à la hausse des perspectives 2026
30/07/2026
T2 2026 : croissance à deux chiffres du chiffre d’affaires et forte progression du BNPA ; révision à la hausse des perspectives 2026 Paris, le 30 juillet 2026 Ventes du T2 en progression de 17,8 % à TCC 1 et BNPA 2 des [...]
QUVIVIQ sales increased 62% year-on-year as Idorsia advances key drivers of future growth
30/07/2026
Ad hoc announcement pursuant to Art. 53 LR QUVIVIQ™ (daridorexant) sales reached CHF 91 million in H1 2026, up 62% year-on-year. Full-year 2026 guidance reaffirmed. Company focused on four key drivers of future growth. [...]
Sugar Reset Drops Label Guide: What the Supplement Facts Panel, Serving Directions, and Safety Statements Disclose for 2026
30/07/2026
Sugar Reset Drops' Chromium Dose, Grapefruit and Licorice Interaction Details, and 20% Refund Fee Explained Largo, FL, July 30, 2026 (GLOBE NEWSWIRE) -- These statements have not been evaluated by the Food and Drug [...]
Ipsen réalise d’excellents résultats au premier semestre 2026 et relève ses objectifs financiers annuels
30/07/2026
Croissance semestrielle du chiffre d’affaires du Groupe de 23,5 % à taux de change constant 1 (20,4 % en données publiées), tirée par une croissance de 24,8 % des ventes du portefeuille de médicaments hors Somatuline [...]
AB2 Bio receives $30 million from Nippon Shinyaku for exclusive U.S. commercialization rights to Tadekinig Alfa
30/07/2026
AB2 Bio receives $30 million from Nippon Shinyaku for exclusive U.S. commercialization rights to Tadekinig Alfa Nippon Shinyaku exercises its exclusive U.S. commercialization option for Tadekinig alfa after AB2 Bio’s [...]
HorseFil Confirms Its Official Website and 2026 Package Pricing Amid Similarly Named Sites
30/07/2026
HorseFil's Tongkat Ali, Maca, and Ashwagandha Amounts, 60-Day Guarantee Terms, and Medication Interaction Details Explained Ogden, UT, July 29, 2026 (GLOBE NEWSWIRE) -- These statements have not been evaluated by the [...]
Pharming reports second quarter and first half 2026 financial results and revises year-end guidance; strong Joenja momentum and near-term clinical readouts to support broader therapeutic use
30/07/2026
For investor audiences and media only Second quarter 2026 total revenues decreased by 3% to US$90.2 million, compared to the second quarter 2025 RUCONEST® revenue was US$72.3 million, a 10% decrease compared to the [...]
Regulated information: Fagron delivers strong H1 2026 performance with 16% topline growth and reiterates FY 2026 guidance
30/07/2026
Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 30 July 2026 – 7:00 AM CET Fagron delivers strong H1 2026 performance with 16% topline growth and reiterates FY 2026 guidance Fagron, the leading [...]
Daxor Broadens Outpatient Footprint with Initiation of ezBVA Lab Diagnostic Services in Kansas
30/07/2026
Commercial Momentum Accelerates as Health System Adopts Turnkey Blood Volume Analysis via CLIA-Certified Send-Out Model OAK RIDGE, TN, July 29, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader [...]
Mesoblast Reports Ryoncil® Net Revenues of US$36M for the Quarter and US$115M for First Full Year of Product Launch
30/07/2026
Expanding indications for RYONCIL in children and adults with life-threatening inflammatory diseases Achieved target of at least 300 Patients treated in Pivotal Phase 3 trial for Chronic Low Back Pain Activity Report [...]
BRAVE Providers, LLC Launches The BRAVE Method, an Organizational Training Program Addressing Vicarious Trauma and Resilience in Trauma-Exposed Organizations
30/07/2026
Developed by trauma psychologist Jenny Hughes, PhD, the evidence-informed training gives groups, agencies, and organizations a shared framework for building vicarious resilience and retaining trauma clinicians. Houston [...]
Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
29/07/2026
- Biologics License Application (BLA) for z-rostudirsen in exon 51 DMD accepted for review by FDA; Priority Review granted; PDUFA target action date set for January 21, 2027 - - Completed enrollment of 71 participants [...]
Onco360® Has Been Selected as a National Pharmacy Partner for VEPPANU™ (vepdegestrant)
29/07/2026
LOUISVILLE, Ky., July 29, 2026 (GLOBE NEWSWIRE) -- Onco360 ® , the nation’s leading independent Specialty Pharmacy, has been selected as a pharmacy partner by Rigel Pharmaceuticals for VEPPANU™ (vepdegestrant), which is [...]

Pages